Abstract
The crystallographic structures of the ternary complexes of human alpha-thrombin with hirugen (a sulfated hirudin fragment) and the small-molecule active site thrombin inhibitors BMS-186282 and BMS-189090 have been determined at 2.6 and 2.8 A. In both cases, the inhibitors, which adopt very similar bound conformations, bind in an antiparallel beta-strand arrangement relative to the thrombin main chain in a manner like that reported for PPACK, D-Phe-Pro-Arg-CH2Cl. They do, however, exhibit differences in the binding of the alkyl guanidine moiety in the specificity pocket. Numerous hydrophilic and hydrophobic interactions serve to stabilize the inhibitors in the binding pocket. Although PPACK forms covalent bonds to both serine and the histidine of the catalytic triad of thrombin, neither BMS-186282 nor BMS-189090 bind covalently and only BMS-186282 forms a hydrogen bond to the serine of the catalytic triad. Both inhibitors bind with high affinity (Ki = 79 nM and 3.6 nM, respectively) and are highly selective for thrombin over trypsin and other serine proteases.
Full Text
The Full Text of this article is available as a PDF (4.9 MB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Rydel T. J., Tulinsky A., Bode W., Huber R. Refined structure of the hirudin-thrombin complex. J Mol Biol. 1991 Sep 20;221(2):583–601. doi: 10.1016/0022-2836(91)80074-5. [DOI] [PubMed] [Google Scholar]
- Shuman R. T., Rothenberger R. B., Campbell C. S., Smith G. F., Gifford-Moore D. S., Gesellchen P. D. Highly selective tripeptide thrombin inhibitors. J Med Chem. 1993 Feb 5;36(3):314–319. doi: 10.1021/jm00055a002. [DOI] [PubMed] [Google Scholar]
- Skrzypczak-Jankun E., Carperos V. E., Ravichandran K. G., Tulinsky A., Westbrook M., Maraganore J. M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J Mol Biol. 1991 Oct 20;221(4):1379–1393. [PubMed] [Google Scholar]
- Skrzypczak-Jankun E., Rydel T. J., Tulinsky A., Fenton J. W., 2nd, Mann K. G. Human D-Phe-Pro-Arg-CH2-alpha-thrombin crystallization and diffraction data. J Mol Biol. 1989 Apr 20;206(4):755–757. doi: 10.1016/0022-2836(89)90582-2. [DOI] [PubMed] [Google Scholar]
- Tabernero L., Chang C. Y., Ohringer S. L., Lau W. F., Iwanowicz E. J., Han W. C., Wang T. C., Seiler S. M., Roberts D. G., Sack J. S. Structure of a retro-binding peptide inhibitor complexed with human alpha-thrombin. J Mol Biol. 1995 Feb 10;246(1):14–20. doi: 10.1006/jmbi.1994.0060. [DOI] [PubMed] [Google Scholar]
- Topol E. J., Bonan R., Jewitt D., Sigwart U., Kakkar V. V., Rothman M., de Bono D., Ferguson J., Willerson J. T., Strony J. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 1993 May;87(5):1622–1629. doi: 10.1161/01.cir.87.5.1622. [DOI] [PubMed] [Google Scholar]
- Weber P. C., Lee S. L., Lewandowski F. A., Schadt M. C., Chang C. W., Kettner C. A. Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs. Biochemistry. 1995 Mar 21;34(11):3750–3757. doi: 10.1021/bi00011a033. [DOI] [PubMed] [Google Scholar]
- van den Bos A. A., Deckers J. W., Heyndrickx G. R., Laarman G. J., Suryapranata H., Zijlstra F., Close P., Rijnierse J. J., Buller H. R., Serruys P. W. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation. 1993 Nov;88(5 Pt 1):2058–2066. doi: 10.1161/01.cir.88.5.2058. [DOI] [PubMed] [Google Scholar]